CLCH is experiencing some internet connectivity issues. For urgent referrals, please contact the Single Point of Access by telephone using the contact numbers for each area. Services are running as normal, so please continue to attend any appointments you have.
FOI/25/254
Read more about this page below
| Reference | FOI/25/254 |
|---|---|
| Description | Semaglutide |
| Date requested | 06/11/2024 |
| Attachments | N/A |
Request
- The number of people who have attended A&E and given Semaglutide as a reason for their visit, where there drug was indicated for weight management - in every year between 2022 and 2024. Please give a figure for each year. Semaglutide also goes under brand names such as Ozempic, Saxenda, Rybelsus and Wegovy – can you please include these names in your records also.
- Please break the figures down to give details of the complications patients presented with as a result of their use of Semaglutide.
Response
Having completed enquiries within the Trust and in respect of Section 1(1)(a), CLCH confirm it does not have a A&E department.